A5043472954- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Gastrointestinal Tumor Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Peptidase Inhibition and Analysis
- Pancreatitis Pathology and Treatment
- Cancer Genomics and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Cancer Diagnosis and Treatment
- Gallbladder and Bile Duct Disorders
- Neuroendocrine Tumor Research Advances
- Helicobacter pylori-related gastroenterology studies
- Metastasis and carcinoma case studies
- Nutrition and Health in Aging
- Prostate Cancer Treatment and Research
- Monoclonal and Polyclonal Antibodies Research
- Renal cell carcinoma treatment
- Cancer, Lipids, and Metabolism
- Epigenetics and DNA Methylation
- Lung Cancer Diagnosis and Treatment
- Glioma Diagnosis and Treatment
Hospital Del Mar
2016-2024
Parc de Salut
2019-2024
Centro de Investigación Biomédica en Red de Cáncer
2018-2022
Hospital del Mar Research Institute
2017-2022
Amsterdam University Medical Centers
2022
Hospital de Especialidades
2021
Centro Medico Nacional Siglo XXI
2021
Universitat Autònoma de Barcelona
2018
Hospital Clínic de Barcelona
2007-2015
Universitat de Barcelona
2009-2013
BackgroundRAS assessment is mandatory for therapy decision in metastatic colorectal cancer (mCRC) patients. This determination based on tumor tissue, however, genotyping of circulating (ct)DNA offers clear advantages as a minimally invasive method that represents heterogeneity. Our study aims to evaluate the use ctDNA an alternative determining baseline RAS status and subsequent monitoring mutations during component routine clinical practice.Patients methodsRAS mutational plasma was...
To compare perioperative outcomes of pancreatoduodenectomy (PD) performed through the laparoscopic route or by open surgery.Laparoscopic PD is being progressively in selected patients.An open-label single-center RCT was conducted between February 2013 and September 2017. The primary endpoint length hospital stay (LOS). Secondary endpoints were operative time, transfusion requirements, specific pancreatic complications (pancreatic biliary fistula, hemorrhage, delayed gastric emptying),...
Previous studies have highlighted the importance of an appropriate human epidermal growth factor receptor 2 (HER2) evaluation for proper identification patients eligible treatment with anti-HER2 targeted therapies. Today, relationship remains unclear between level HER2 amplification and outcome HER2-positive gastric cancer treated first-line chemotherapy trastuzumab. The aim this study was to determine whether gene determined by HER2/CEP17 ratio copy number could significantly predict some...
Abstract Microwave (MWA) and radiofrequency ablation (RFA) are main ablative techniques for hepatocellular carcinoma (HCC) colorectal liver metastasis (MT). This randomized phase 2 clinical trial compares the effectiveness of MWA RFA as well morphology corresponding zones. HCC MT patients with 1.5–4 cm tumors, suitable ablation, were into or Groups. The primary endpoint was short-to-long diameter ratio zone (SLR). Primary technical success (TS) a cumulative local tumor progression (LTP)...
The choice of chemotherapy in HER2-negative gastric cancer is based on centre's preferences and adverse effects profile. No schedule currently accepted as standard, nor are there any factors to predict response, other than HER2 status. We seek evaluate whether Lauren type influences the efficacy various chemotherapies patient overall survival (OS). have conducted a multicenter study 31 hospitals. eligibility criteria include diagnosis stomach or gastroesophageal junction adenocarcinoma,...
Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, ultimately develop disease progression, often driven by acquisition of mutations the extracellular domain (ECD) EGFR. Sym004 is a novel 1:1 mixture two nonoverlapping mAbs that recently showed promising activity phase I trial MCRC. Our aim was to determine efficacy circumvent resistance EGFR ECD mutations.Functional studies were performed...
Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms acquired resistance trastuzumab in by using well-established cell line-based preclinical models, as well samples from patients with HER2-positive treated trastuzumab. studied NCI-N87 and OE19, two lines that overexpress HER2 receptor are sensitive. Differences at protein, DNA, RNA levels between parental resistant cells were...
Abstract BACKGROUND Previous work showed that the NF‐κB survival pathway is activated by docetaxel (D) and contributes to D resistance in prostate cancer. In this study we aimed investigate dynamics of relationship between IL‐6 shift from D‐naive castration‐resistant cancer (CRPC) D‐resistance patients cell lines. METHODS CRPC tumor samples were tested for NF‐κB/p65 immunohistochemistry. treated with also serum (ELISA). Two D‐resistant lines, PC‐3R DU‐145R, derived cells PC‐3 DU‐145,...
CA 19.9 serum levels were prospectively determined in 573 patients admitted to hospital for suspicion of pancreatic cancer. The final diagnosis was 77 with no malignancy, 389 cancer, 37 neuroendocrine 28 cholangiocarcinomas, 4 gallbladder 27 ampullary carcinomas, and 11 periampullary carcinomas. using a commercial assay from Roche Diagnostics, U/ml considered as the upper limit normality. Abnormal found 27%, 81.5%, 85.7%, 59.3%, 63.6%, 18.9% benign diseases, ampullary, periampullary, or...
To develop and validate a nomogram web-based calculator to predict overall survival (OS) in Caucasian-advanced oesophagogastric adenocarcinoma (AOA) patients undergoing first-line combination chemotherapy. Nine hundred twenty-four AOA treated at 28 Spanish teaching hospitals from January 2008 September 2014 were used as derivation cohort. The result of an adjusted-Cox proportional hazards regression was represented calculator. model validated 502 prospectively recruited between October...
// Neus Martinez-Bosch 1, * , Luis E. Barranco 2, Carlos A. Orozco Mireia Moreno 1 Laura Visa 3 Mar Iglesias 4 Lucy Oldfield 5 John P. Neoptolemos 6 William Greenhalf Julie Earl 7 Alfredo Carrato Eithne Costello and Pilar Navarro 8 Cancer Research Program, IMIM, Hospital del Medical Institute, Unidad Asociade CSIC, Barcelona, Spain 2 Department of Gastroenterology, Universidad Autonoma de Mar, Oncology, Pathology, CIBERONC, Molecular Clinical Medicine, Institute Translational University...
ABSTRACT Patients requiring surgery for locally advanced esophagogastric cancer often require neoadjuvant therapy (NAT), which may have a detrimental impact on cardiorespiratory reserve. The aims of this study were to investigate the feasibility and tolerability 5-week preoperative high-intensity interval training program after NAT, assess potential effects protocol exercise capacity, muscle function, health-related quality life (HRQL). We prospectively studied consecutive patients with...
Research into cancer-associated thrombosis (CAT) entails managing dynamic data that pose an analytical challenge. Thus, methods assume proportional hazards to investigate prognosis entail a risk of misinterpreting or overlooking key traits time-varying effects. We examined the AGAMENON registry, which collects from 2,129 patients with advanced gastric cancer. An accelerated failure time (AFT) multistate model and flexible competing risks regression were used scrutinize effect CAT, as well...
Serum 25-hydroxyvitamin D3 (Vitamin D) insufficiency and single-nucleotide polymorphisms (SNPs) on its receptor, Vitamin D receptor (VDR), have been reported to be involved in melanoma susceptibility populations mostly from northern countries. To investigate levels VDR SNPs patients sunny area of Barcelona, two studies were carried out. The first study evaluated the at time diagnosis second one analyzed association between genetic variants risk having a high nevus number, strongest...
Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns use and the results achieved actual clinical practice.The study population comprised patients with AGC AGAMENON registry who had received second-line. The objective was describe pattern second-line therapies administered, progression-free following (PFS-2), post-progression since first-line (PPS).2311 cases 2066 progression events (89.3%) were recorded;...
There is currently no consensus regarding first-line chemotherapy for patients with advanced gastric cancer (AGC) who are ineligible to receive trastuzumab. The objective of this study was evaluate the efficacy and tolerance triplets versus doublets by analyzing a national registry.Patients AGC treated polychemotherapy without associating trastuzumab were included from 2008 through 2016. effect compared using 3 methods: Cox proportional hazards regression, propensity score matching (PSM),...